Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carboplatin radiosensitization and isotretinoin maintenance in high-risk medulloblastoma/PNET
NL-OMON41634Active, not recruiting
- Sponsor
- International: Children's Oncology Group (COG) Netherlands: Dutch Childhood Oncology Group (DCOG) Childhood Oncology Group (COG) COG Operations Center 440 E. Huntington Drive, 4th Floor Arcadia, CA 91006-3776 USA Tel: (626) 447-0064
- Start
- Apr 2011
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of carboplatin and isotretinoin in medulloblastoma and primitive neuroectodermal tumor (PNET) (4 arms), sponsored by International: Children's Oncology Group (COG) Netherlands: Dutch Childhood Oncology Group (DCOG) Childhood Oncology Group (COG) COG Operations Center 440 E. Huntington Drive, 4th Floor Arcadia, CA 91006-3776 USA Tel: (626) 447-0064. Primary endpoints: Long-term event-free survival after carboplatin radiosensitization and Long-term event-free survival after isotretinoin. Started Apr 2011; status: active, not recruiting.
02
Drugs
carboplatinisotretinoin
03
Conditions
medulloblastomaprimitive neuroectodermal tumor (PNET)
Beyond the preview
Go deeper on NL-OMON41634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41634.